Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Patricia M. Plezia"'
Autor:
Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano, Daniel E. Haggstrom, Matei P. Socoteanu, David A. Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng J. Ong, Alexandra Sanford, Katayoun Amiri, Jonathan W. Goldman, Jared Weiss, on behalf of the ABOUND.70+ Investigators, Ajeet Gajra, Andrei Dobrescu, Bohdan E. Halibey, Corey Langer, Daniel Haggstrom, Eric Anderson, Eugene H. Paschold, Haiying Cheng, Haythem Ali, Hossein Borghaei, Jawad Elias Francis, Ayla Ahmed Kessler, Jen C. Wang, Jonathan Wade Goldman, Jose E. Najera, Nadim F. Nimeh, Joseph Rosales, Konstantin H. Dragnev, Leonardo Forero, Lynne A. Bui, Marc R. Matrana, Maurice Willis, Monika Joshi, Morton Coleman, Moses Sundar Raj, Navkiranjit Gill, Patricia M. Plezia, Manuel R. Modiano, R. Timothy Webb, Rita Axelrod, Robert Andrew Dichmann, Ronald P. Harris, Scott Anthony Sonnier, Vijay Patel, Shaker R. Dakhil, Tarek Mekhail, Thomas Hensing, Tony M. Samaha, Vicky Lee, Kimberly McGregor, William Eyre Lawler, William L. Skinner, William T. DeRosa
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally adv
Externí odkaz:
https://doaj.org/article/6b1a3f05e7d740d8aebb050cd6890afd
Autor:
Manuel Modiano, Patricia M. Plezia, Susan MacDonald, Angela Marini, Niramol Savaraj, Bijan Almassian, Jessica Fischer, Lynn G. Feun, King C. Lee, John Mao, Elizabeth Colacino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 50:223-229
Purpose. To perform a phase I and pharmacokinetics study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) a new ribonucleotide reductase inhibitor using a single intravenous (2-h) schedule every 4 weeks. 3-AP was given at a starting dose
Autor:
Tauseef Ahmed, Paul Baskind, Monika Baier, Y. M. Peng, Eric J. Feldman, A. Mittelman, Z. A. Arlin, David S. Alberts, Patricia M. Plezia
Publikováno v:
Journal of Clinical Oncology. 11:2002-2009
PURPOSE To determine the maximally tolerated dose of mitoxantrone in combination with cytarabine in patients with acute leukemia and advanced phases of chronic myelogenous leukemia (CML), and to assess the pharmacokinetics of high-dose mitoxantrone i
Autor:
Yei Mei Peng, Gerald B. Grindey, Marta Hamilton, Thomas M. McCloskey, Charles W. Taylor, Denise J. Roe, David S. Alberts, David E. Seitz, Patricia M. Plezia, Monika Matzner
Publikováno v:
JNCI Journal of the National Cancer Institute. 84:1798-1802
BACKGROUND Sulofenur is a diarylsulfonylurea with demonstrated antitumor activity in patients with advanced epithelial ovarian cancer refractory to standard chemotherapy. The dose-limiting toxic effects observed in phase I clinical trials have been a
Autor:
Scott S. Emerson, Y. M. Peng, Patricia M. Plezia, David S. Alberts, H. L. Gensler, S. M. Sayers, Y. Liu, M. J. Xu, Cheryl Ritenbaugh
Publikováno v:
JNCI Journal of the National Cancer Institute. 84:1559-1565
BACKGROUND Beta-carotene is one of the most commonly used compounds in clinical trials of chemopreventive agents in various neoplastic diseases. Animal studies, including our own, have documented that dietary beta-carotene can reduce plasma alpha-toc
Autor:
Nancy Mason-Liddil, J. G. Phillips, David S. Alberts, Denise J. Roe, Patricia M. Plezia, Robert F. Struck, Robert T. Dorr
Publikováno v:
JNCI Journal of the National Cancer Institute. 83:1739-1743
We previously reported that cimetidine but not ranitidine significantly enhances cyclophosphamide-induced bone marrow toxic effects and the appearance of cyclophosphamide alkylating species in a murine leukemia mouse model, and we advised caution in
Autor:
Denise J. Roe, Patricia M. Plezia, Manfred Lehnert, Thomas M. Grogan, William S. Dalton, Sydney E. Salmon, Thomas P. Miller
Publikováno v:
Blood. 78:44-50
Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials. Bone marrows from 59 myeloma patients in relapse were evaluated for several resistance parameters: expression of
Publikováno v:
The American Journal of Clinical Nutrition. 53:90-94
The effects of various doses (0, 15, 30, 45, and 60 mg/d) of supplementary beta-carotene were evaluated. The percentage of lymphoid cells with surface markers for T-helper and natural killer (NK) cells and cells with interleukin 2 (IL-2) and transfer
Autor:
Judy L. Chase, David S. Alberts, Denise J. Roe, Patricia M. Plezia, Patricia L. Berens, John F. Kessler
Publikováno v:
Journal of Pain and Symptom Management. 5:101-108
In a randomized open crossover study, the antiemetic efficacy of a five-drug antiemetic regimen consisting of metoclopramide, dexamethasone, diazepam, diphenhydramine, and thiethylperazine was compared to that of high-dose metoclopramide. Thirteen pa
Autor:
Patricia M. Plezia, William F. Hahne, Dan C. Dimmitt, Michael B. Cramer, Lori Martin, Christina Lippert
Publikováno v:
American journal of therapeutics. 6(3)
Dolasetron mesylate (MDL 73,147, Anzemet, Hoechst Marion Roussel, Kansas City, MO) is a 5-HT ( 3 ) receptor antagonist undergoing clinical evaluation as an antiemetic agent. Dolasetron is rapidly metabolized to form hydrodolasetron (MDL 74,156). The